Cargando…

High-Density Lipoprotein Lipidomics and Mortality in CKD

RATIONALE & OBJECTIVE: Patients with chronic kidney disease (CKD) have dysfunctional high-density lipoprotein (HDL) particles that lack cardioprotective properties; altered lipid composition may be associated with these changes. To investigate HDL lipids as potential cardiovascular risk factors...

Descripción completa

Detalles Bibliográficos
Autores principales: Lidgard, Benjamin, Hoofnagle, Andrew N., Zelnick, Leila R., de Boer, Ian H., Fretts, Amanda M., Kestenbaum, Bryan R., Lemaitre, Rozenn N., Robinson-Cohen, Cassianne, Bansal, Nisha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10507644/
https://www.ncbi.nlm.nih.gov/pubmed/37731962
http://dx.doi.org/10.1016/j.xkme.2023.100708
_version_ 1785107359160336384
author Lidgard, Benjamin
Hoofnagle, Andrew N.
Zelnick, Leila R.
de Boer, Ian H.
Fretts, Amanda M.
Kestenbaum, Bryan R.
Lemaitre, Rozenn N.
Robinson-Cohen, Cassianne
Bansal, Nisha
author_facet Lidgard, Benjamin
Hoofnagle, Andrew N.
Zelnick, Leila R.
de Boer, Ian H.
Fretts, Amanda M.
Kestenbaum, Bryan R.
Lemaitre, Rozenn N.
Robinson-Cohen, Cassianne
Bansal, Nisha
author_sort Lidgard, Benjamin
collection PubMed
description RATIONALE & OBJECTIVE: Patients with chronic kidney disease (CKD) have dysfunctional high-density lipoprotein (HDL) particles that lack cardioprotective properties; altered lipid composition may be associated with these changes. To investigate HDL lipids as potential cardiovascular risk factors in CKD, we tested the associations of HDL ceramides, sphingomyelins, and phosphatidylcholines with mortality. STUDY DESIGN: We leveraged data from a longitudinal prospective cohort of participants with CKD. SETTING & PARTICIPANTS: We included participants aged greater than 21 years with CKD, excluding those on maintenance dialysis or with prior kidney transplant. EXPOSURE: HDL particles were isolated using density gradient ultracentrifugation. We quantified the relative abundance of HDL ceramides, sphingomyelins, and phosphatidylcholines via liquid chromatography tandem mass spectrometry (LC-MS/MS). OUTCOMES: Our primary outcome was all-cause mortality. ANALYTICAL APPROACH: We tested associations using Cox regressions adjusted for demographics, comorbid conditions, laboratory values, medication use, and highly correlated lipids with opposed effects, controlling for multiple comparisons with false discovery rates (FDR). RESULTS: There were 168 deaths over a median follow-up of 6.12 years (interquartile range, 3.71-9.32). After adjustment, relative abundance of HDL ceramides (HR, 1.22 per standard deviation; 95% CI, 1.06-1.39), sphingomyelins with long fatty acids (HR, 1.44; 95% CI, 1.05-1.98), and saturated and monounsaturated phosphatidylcholines (HR, 1.22; 95% CI, 1.06-1.41) were significantly associated with increased risk of all-cause mortality (FDR < 5%). LIMITATIONS: We were unable to test associations with cardiovascular disease given limited power. HDL lipidomics may not reflect plasma lipidomics. LC-MS/MS is unable to differentiate between glucosylceramides and galactosylceramides. The cohort was comprised of research volunteers in the Seattle area with CKD. CONCLUSIONS: Greater relative HDL abundance of 3 classes of lipids was associated with higher risk of all-cause mortality in CKD; sphingomyelins with very long fatty acids were associated with a lower risk. Altered lipid composition of HDL particles may be a novel cardiovascular risk factor in CKD. PLAIN-LANGUAGE SUMMARY: Patients with chronic kidney disease have abnormal high-density lipoprotein (HDL) particles that lack the beneficial properties associated with these particles in patients with normal kidney function. To investigate if small lipid molecules found on the surface of HDL might be associated with these changes, we tested the associations of lipid molecules found on HDL with death among patients with chronic kidney disease. We found that several lipid molecules found on the surface of HDL were associated with increased risk of death among these patients. These findings suggest that lipid molecules may be risk factors for death among patients with chronic kidney disease.
format Online
Article
Text
id pubmed-10507644
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-105076442023-09-20 High-Density Lipoprotein Lipidomics and Mortality in CKD Lidgard, Benjamin Hoofnagle, Andrew N. Zelnick, Leila R. de Boer, Ian H. Fretts, Amanda M. Kestenbaum, Bryan R. Lemaitre, Rozenn N. Robinson-Cohen, Cassianne Bansal, Nisha Kidney Med Original Research RATIONALE & OBJECTIVE: Patients with chronic kidney disease (CKD) have dysfunctional high-density lipoprotein (HDL) particles that lack cardioprotective properties; altered lipid composition may be associated with these changes. To investigate HDL lipids as potential cardiovascular risk factors in CKD, we tested the associations of HDL ceramides, sphingomyelins, and phosphatidylcholines with mortality. STUDY DESIGN: We leveraged data from a longitudinal prospective cohort of participants with CKD. SETTING & PARTICIPANTS: We included participants aged greater than 21 years with CKD, excluding those on maintenance dialysis or with prior kidney transplant. EXPOSURE: HDL particles were isolated using density gradient ultracentrifugation. We quantified the relative abundance of HDL ceramides, sphingomyelins, and phosphatidylcholines via liquid chromatography tandem mass spectrometry (LC-MS/MS). OUTCOMES: Our primary outcome was all-cause mortality. ANALYTICAL APPROACH: We tested associations using Cox regressions adjusted for demographics, comorbid conditions, laboratory values, medication use, and highly correlated lipids with opposed effects, controlling for multiple comparisons with false discovery rates (FDR). RESULTS: There were 168 deaths over a median follow-up of 6.12 years (interquartile range, 3.71-9.32). After adjustment, relative abundance of HDL ceramides (HR, 1.22 per standard deviation; 95% CI, 1.06-1.39), sphingomyelins with long fatty acids (HR, 1.44; 95% CI, 1.05-1.98), and saturated and monounsaturated phosphatidylcholines (HR, 1.22; 95% CI, 1.06-1.41) were significantly associated with increased risk of all-cause mortality (FDR < 5%). LIMITATIONS: We were unable to test associations with cardiovascular disease given limited power. HDL lipidomics may not reflect plasma lipidomics. LC-MS/MS is unable to differentiate between glucosylceramides and galactosylceramides. The cohort was comprised of research volunteers in the Seattle area with CKD. CONCLUSIONS: Greater relative HDL abundance of 3 classes of lipids was associated with higher risk of all-cause mortality in CKD; sphingomyelins with very long fatty acids were associated with a lower risk. Altered lipid composition of HDL particles may be a novel cardiovascular risk factor in CKD. PLAIN-LANGUAGE SUMMARY: Patients with chronic kidney disease have abnormal high-density lipoprotein (HDL) particles that lack the beneficial properties associated with these particles in patients with normal kidney function. To investigate if small lipid molecules found on the surface of HDL might be associated with these changes, we tested the associations of lipid molecules found on HDL with death among patients with chronic kidney disease. We found that several lipid molecules found on the surface of HDL were associated with increased risk of death among these patients. These findings suggest that lipid molecules may be risk factors for death among patients with chronic kidney disease. Elsevier 2023-08-06 /pmc/articles/PMC10507644/ /pubmed/37731962 http://dx.doi.org/10.1016/j.xkme.2023.100708 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Research
Lidgard, Benjamin
Hoofnagle, Andrew N.
Zelnick, Leila R.
de Boer, Ian H.
Fretts, Amanda M.
Kestenbaum, Bryan R.
Lemaitre, Rozenn N.
Robinson-Cohen, Cassianne
Bansal, Nisha
High-Density Lipoprotein Lipidomics and Mortality in CKD
title High-Density Lipoprotein Lipidomics and Mortality in CKD
title_full High-Density Lipoprotein Lipidomics and Mortality in CKD
title_fullStr High-Density Lipoprotein Lipidomics and Mortality in CKD
title_full_unstemmed High-Density Lipoprotein Lipidomics and Mortality in CKD
title_short High-Density Lipoprotein Lipidomics and Mortality in CKD
title_sort high-density lipoprotein lipidomics and mortality in ckd
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10507644/
https://www.ncbi.nlm.nih.gov/pubmed/37731962
http://dx.doi.org/10.1016/j.xkme.2023.100708
work_keys_str_mv AT lidgardbenjamin highdensitylipoproteinlipidomicsandmortalityinckd
AT hoofnagleandrewn highdensitylipoproteinlipidomicsandmortalityinckd
AT zelnickleilar highdensitylipoproteinlipidomicsandmortalityinckd
AT deboerianh highdensitylipoproteinlipidomicsandmortalityinckd
AT frettsamandam highdensitylipoproteinlipidomicsandmortalityinckd
AT kestenbaumbryanr highdensitylipoproteinlipidomicsandmortalityinckd
AT lemaitrerozennn highdensitylipoproteinlipidomicsandmortalityinckd
AT robinsoncohencassianne highdensitylipoproteinlipidomicsandmortalityinckd
AT bansalnisha highdensitylipoproteinlipidomicsandmortalityinckd